CClinicalTrials.gg
CompletedNCT07341568Updated Jan 14, 2026

Exercise-Modulated Cognitive Hormones

An observational study in Cognitive Impairment and Healthy Participants, sponsored by King Saud University. Completed at 1 site in Saudi Arabia. Open to participants aged 50 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-14.

Sponsored by King Saud University · Observational

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
60
Ages
50 Years to 80 Years
Sex
All
01

Study summary

Investigating the influence of a 12-week exercise regimen structured thrice weekly on cognitive capacity, and related hormones like Leptin, Irisin, BDNF hormones, antioxidant status, and inflammatory cytokines, whether these modulations potentially enhance neuroprotection and mitigate age-related cognitive impairment among healthy adults.

Read the detailed description

To elucidate the potential role of exercise as a buffer of cognitive impairment among healthy adults. We thought to investigate the effect of supervised aerobic training of moderate intensity on related hormones like Leptin, Irisin, BDNF hormones, antioxidant status, and inflammatory cytokines, whether these modulations potentially enhance neuroprotection and mitigate age-related cognitive impairment among healthy adults.

02

Conditions studied

  • Cognitive Impairment
  • Healthy Participants

Keywords

  • cognitive capacity, Leptin, Irisin, BDNF hormones
03

In context

Cognitive Dysfunction

3,843 studies on the registry are indexed under Cognitive Dysfunction; 1,100 are open to participants now.

This study's enrollment of 60 is below the median of 150 across 950 observational studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

King Saud University is the lead sponsor of 164 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Sixty healthy individuals, aged 50 to 80 years (30 men/30 women), were invited to participate in this study after provided with informed consent.

Inclusion criteria

  • Sixty healthy individuals, aged 50 to 80 years (30 men/30 women), were invited to participate in this study after provided with informed consent and were included in this study. Also, all participants were of a sedentary lifestyle, with little or no physical activity during daily routine activities like work and transportation

Exclusion criteria

Exclusion Criteria:

  • To ensure accurate results, participants with obesity (BMI) ≥35 kg/m2.), physical impairments, movement limitations, chronic illnesses, such as kidney or liver diseases, or severe diabetes-related complications such as neuropathy, retinopathy, neuromuscular issues, cardiopulmonary conditions, or disorders affecting eating, the endocrine system, immune system, or mental health or those who undergoing glucocorticoid medication were excluded from this study
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
60 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • participants with cognitive impairment

    subjects with cognitive imparment as measured by the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) battery.

  • healthy goup

    Subjects are healthy without any diseases and are normal as estimated by the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) battery.

06

What researchers measure

Primary outcomes

  1. Assessment of cognitive abilities

    Trained research assistants assessed the cognitive abilities of older adult's pre and post supervised aerobic exercise using the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) battery. Assessments required between 45 and 90 minutes.

    Time frame: 6 months

  2. 2- Leisure-time physical activity (LTPA)

    A verified questionnaire was utilized to assess physical activity, specifically focusing on leisure-time physical activity (LTPA). In alignment with previous findings, we measured the weekly energy expenditure in terms of metabolic equivalents per hour per week (T-LPTA-MET/H/W

    Time frame: 6 months

  3. 3-Assessment of apoptotic-related proteins

    Blood serum samples were collected from all participants in the early hours after a night of fasting, both before and after the exercise training regimen, to analyze apoptosis-related proteins. Immunoassay methods were used to measure serum Bcl-2 and cytochrome c levels. This involved using ELISA kits specifically designed for Bcl-2 (Cat# QIA23, Oncogene Research Products, Germany) and cytochrome c (Zymed ELISA Kit, Cat. No. 99-0040). Furthermore, the quantification of p53 concentration in the serum was determined utilizing a single-step enzyme-immunoassay ELISA kit (Catalog Number 11 828 789 001; Roche Diagnostics GmbH, Roche Applied Science, Germany) based on photometric methods.

    Time frame: 6 month

Secondary outcomes

  1. biochemical analysis of hormones, antioxidant enzymes, before and after exercise training

    The levels of Leptin, Irisin, BDNF hormones, antioxidant status, and inflammatory cytokines were identified from the serum of all subjects, healthy and cognitively impaired subjects, before and after exercise sessions

    Time frame: 6 month

07

Study locations

1 site
  • King Saud University
    Riyadh, Saudi Arabia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07341568
Lead sponsor
King Saud University
Responsible party
Sami Gabr (clinical Professor, King Saud University) — Principal investigator
First posted
Jan 14, 2026
Start date
Jun 15, 2025
Primary completion
Oct 30, 2025
Completion
Nov 30, 2025
Last update
Jan 14, 2026

Study contacts

Sami Gabr
principal investigator · Medical Microbiology Dept, ImmunityUnit,Faculty of Medicine, Mansoura University, Egypt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion